Higher lung cancer risk among female never-smokers than males in a large married couple study [0.03%]
大型夫妻对照研究中终身不吸烟女性肺癌风险高于男性
Hui Cai,Xiao-Ou Shu,Shenghui Wu et al.
Hui Cai et al.
Background: Whether female being more susceptible to lung cancer among never smokers (LCNS) than males has been a long-standing debate. Method: ...
Immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer patients with preexisting pulmonary emphysema or interstitial lung abnormalities [0.03%]
自身免疫检查点抑制剂诱导的非小细胞肺癌合并肺气肿或间质性肺病患者的免疫相关性肺炎
Xi Chen,Caijuan Huan,Piao Yang et al.
Xi Chen et al.
Background: Immune checkpoint inhibitor-induced interstitial lung disease (ICI-ILD) is a serious adverse event. While interstitial lung abnormalities (ILA) are known risk factors, the role of preexisting pulmonary emphyse...
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases [0.03%]
一线免疫治疗联合或不联合化疗以及是否进行初始立体定向放射治疗(SRT)在无症状脑转移的非小细胞肺癌(NSCLC)患者中的应用
Lorenz Frehner,Sämi Schär,Stefanie Hayoz et al.
Lorenz Frehner et al.
Background: The role and optimal timing of SRT for patients with advanced NSCLC and asymptomatic brain metastases treated with immune checkpoint inhibitors (ICI) are controversial. ...
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study [0.03%]
帕博利珠单抗对比帕博利珠单抗联合化疗一线治疗晚期非小细胞肺癌患者长期生存的多中心倾向性匹配队列研究
Nao Shoshihara,Kinnosuke Matsumoto,Takayuki Shiroyama et al.
Nao Shoshihara et al.
Background: Pembrolizumab is currently used as a first-line therapy for EGFR- and ALK-negative advanced non-small cell lung cancer (NSCLC). However, whether pembrolizumab alone (P-mono) or combined with platinum chemother...
Clinical impact of preoperative adipopenia on postoperative outcomes in non-small cell lung cancer surgery [0.03%]
术前脂肪消耗对非小细胞肺癌术后结果的影响分析
Atsuki Uchibori,Satoru Okada,Masanori Shimomura et al.
Atsuki Uchibori et al.
Background: This study aimed to clarify the relationship between preoperative adipopenia and clinicopathological factors, including sarcopenia and myosteatosis, in patients with surgically resected non-small cell lung can...
A novel agent, p-toluenesulfonamide, in the management of malignant pleural effusions [0.03%]
恶性胸腔积液的新型药物p-托仑磺胺的临床研究
Yung-Hung Luo,Chuan-Ching Yang,Shun-Chi Wu et al.
Yung-Hung Luo et al.
Background: Malignant pleural effusion (MPE) is the lethal consequence of various human cancers metastatic to the pleural cavity, with unclear underlying mechanisms and limited effective treatments. Current therapies, suc...
The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer [0.03%]
表皮生长因子受体酪氨酸激酶抑制剂和/或化疗作为完全切除的IIIA期非小细胞肺癌术后辅助治疗初探及其五年生存分析研究
Wenyan Ma,Baicheng Zhao,Yukuan Lang et al.
Wenyan Ma et al.
Introduction: Adjuvant chemotherapy or/and adjuvant Epidermal Growth Factor Receptor tyrosine kinase inhibitor (EGFR-TKI) therapy are commonly used to treat completely resected non-small cell lung cancer (NSCLC) with EGFR...
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS study [0.03%]
拉索替尼联合培美曲塞治疗表皮生长因子受体突变阳性非小细胞肺癌脑膜转移患者Ⅱ期临床研究：Lazarus研究（KCSG LU 21-01）
Hyun Ae Jung,Tae Min Kim,Hye Ryun Kim et al.
Hyun Ae Jung et al.
Purpose: Lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated high blood-brain barrier (BBB) penetration in preclinical studies. Similarly, pemetrexed has show...
Factors associated with lung cancer-specific mortality in lung cancer screening programs [0.03%]
与肺癌筛查项目中肺癌特异性死亡率相关的因素
Esther Tannoury,Suzanne C Byrne,Mark M Hammer
Esther Tannoury
Objectives: Two major clinical trials have proven lung cancer screening (LCS) to be effective in reducing lung cancer-specific mortality. However, mortality reduction in the trials was only 20%. Our objective is to identi...
The immune desert tumor microenvironment in Thoracic SMARCA4-deficient undifferentiated tumors: spatial distribution characteristics and prognostic significance [0.03%]
胸腔SMARCA4基因缺陷型未分化肿瘤免疫荒漠型肿瘤微环境的特征及预后意义
Xiaotao Wang,Wenwen Shi,Yang Xiao et al.
Xiaotao Wang et al.
Introduction: Thoracic SMARCA4-Deficient Undifferentiated Tumors (SMARCA4-UT) are highly aggressive malignancies with poor prognosis. There is currently no standardized treatment strategy. We aimed to investigate the char...